acta 2_2015

More documents

Recommendations

Info

232 ZAHRA SAFAEI et al.Concetration (µg/mnL)Figure. 2. Mean plasma concentration-time profile of fluconazole in healthy volunteers (n = 12) after a single 150 mg of fluconazoleTable 4. Pharmacokinetic parameters of fluconazole in healthyvolunteers following a single oral dose of 150 mg of fluconazole.ParameterResult (mean ± SD)T max (h) 2.62 ± 0.40C max (µg/mL) 2.22 ± 0.46AUC 0-t (µg×h/mL) 73.26 ± 20.29AUC 0-∞ (µg×h/mL) 91.18 ± 28.54K el (h -1 ) 0.024 ± 0.004thus proving suitability of the method. In this study,plasma concentrations were determined in twelvehealthy volunteers, who received 150 mg of fluconazoleeach. Figure 2 shows the mean plasmaconcentration-time profile of fluconazole. Thederived pharmacokinetic parameters of 12 healthyvolunteers are summarized in Table 4. These pharmacokineticparameters are in good agreement withthose found previously (4).AcknowledgmentThis work was supported by Noor Researchand Educational Institute.REFERENCES1. Bennett J.E.: Antifungal Agents, in ThePharmacological Basis of Therapeutics.Goodman-Gilman A., Rall T.W., Nies A.S.,Taylor P. Eds., p. 1172, McGraw-Hill,Singapore 1992.2. Goa K.L., Barredell L.B.: Drugs 50, 658 (1995).3. Surber C.: in Drug Concentrations in the Skin.Mailbach H.I. Ed., p. 151, CRC Press, BocaRaton 1996.4. Grant S.M., Clissold S.P.: Drugs 39, 877(1990).5. Humphrey M.J., Jevons S., Tarbit M.H.:Antimicrob. Agents Chemother. 28, 648 (1985).6. Anaissie E., Kontoyiannis D.P., Huls C.,Vartivarian S., Karl C., Prince R.A., Bosso J.,Bodey G.P.: J. Infect. Dis. 172, 599 (1995).7. Cameron M.L., Schell W.A., Bruch S., BartlettJ.A., Waskin H.A., Perfect J.: Antimicrob.Agents Chemother. 37, 2449 (1993).8. Ghannoum M.A., Rex J.H., Galgiani J.N.: J.Clin. Microbiol. 34, 489 (1996).9. Graybill J.R., Najvar L.K., Holmberg J.D.,Correa A., Luther M.F.: Antimicrob. AgentsChemother. 39, 2197 (1995).10. Louie A., Liu Q.F., Drusano G.L., Liu W.,Mayers M., Anaissie E., Miller M.H.:Antimicrob. Agents Chemother. 42, 1512(1998).11. Radetsky M., Wheeler R.C., Roe M.H., ToddJ.K.: J. Clin. Microbiol. 24, 600 (1986).12. Rex J.H., Nelson P.W., Paetznick V.L., Lozano-Chiu M., Espinel-Ingroff A., Anaissie E.:Antimicrob. Agents Chemother. 42, 129 (1998).13. Rex J.H., Pfaller M.A., Galgiani J.N., BartlettJ.A., Espinel-Ingroff A., Ghannoum M.A.,
Determination of fluconazole in human plasma by reverse phase... 233Lancaster M. et al.: Clin. Infect. Dis. 24, 235(1997).14. Craig W.A.: Clin. Infect. Dis. 26, 1 (1998).15. Santos S.R.C.J., Campos E.V., Sanches C.,Gomez D.S., Ferreira M.C.: Clinics 65, 237(2010).16. Marchetti O., Majcherczyk P.A., Glauser M.P.,Bille J., Moreillon P., Sanglard D.: Antimicrob.Agents Chemother. 45, 696 (2001).17. Evrard P.A., Derrider G., Verbeeck R.K.:Pharm. Res. 13, 12 (1996).18. Menacherry S., Hubert W., Justice J.B.: Anal.Chem. 64, 577 (1992).19. Stahle L., Segersv‰rd S., Ungerstedt U.: J.Pharmacol. Methods 25, 41 (1991).20. Rex J.H., Hanson L.H., Armantea M.A.,Stevens D.A., Bennet J.E.: Antimicrob. AgentsChemother. 35, 846 (1991).21. Jacobson I., Sandberg M., Hamberger A.: J.Neurosci. Methods 15, 263 (1985).22. Mathy F.X., Preat V., Verbeeck R.K.: J. Pharm.Sci. 90, 1897 (2001).23. Verbeeck R.K.: Adv. Drug Deliv. Rev. 45, 217(2000).24. Jovanovic D., Killibarda V., Ciric B.: Clin.Ther. 27, 1588 (2005).25. Wattananat T., Wiyada A.: BiomedChromatogr. 20, 1 (2006).26. Egle H., Trittler R., K¸mmerer K.: Ther. DrugMonit. 26, 425 (2004).27. Ng T.K.C., Chan R.C.Y., Adeyemi-DoroF.A.B., Cheung S.W., Cheng A.F.B.: J.Antimicrob. Chemother. 37, 465 (1996).28. Cociglio M., Brandissou S., Alric R., BressolleF.: J. Chromatogr. B 686, 11 (1996).29. Koks C.H.W., Rosing H., Meenhorst P.L., BultA., Beijnen J.H.: J. Chromatogr. B 663, 435(1994).30. Wallace J.E., Harris S.C., Gallegos J., FouldsG., Chen T.J., Rinaldi M.G.: Antimicrob.Agents Chemother. 36, 603 (1992).31. Flores-Murrieta F.J., Granados-Soto V., HongE.: J. Liq. Chromatogr. Relat. Technol. 17, 3803(1994).32. Inagaki K., Takagi J., Lor E., Okamoto M.P.,Gill M.A.: Ther. Drug Monit. 14, 306 (1992).Received: 30. 05. 2014
Page 4: PHARMACEUTICAL TECHNOLOGY347. £uka
Page 11: Impact of stress factors on optical
Page 14 and 15: 228 ZAHRA SAFAEI et al.the determin
Page 16 and 17: 230 ZAHRA SAFAEI et al.respectively
Page 21 and 22: Acta Poloniae Pharmaceutica ñ Drug
Page 23 and 24: Lipophilicity assessment of spirono
Page 31: Acta Poloniae Pharmaceutica ñ Drug
Page 34 and 35: 248 ASHFAQ AHMAD et al.Proposed mec
Page 36 and 37: 250 ASHFAQ AHMAD et al.Figure 5. Re
Page 38 and 39: 252 ASHFAQ AHMAD et al.4. Ha H., Pa
Page 40 and 41: 254 PRITESH DEVBHUTI et al.inversel
Page 42 and 43: 256 PRITESH DEVBHUTI et al.Figure 1
Page 44 and 45: 258 PRITESH DEVBHUTI et al.received
Page 46 and 47: 260 PRITESH DEVBHUTI et al.20. Khia
Page 48 and 49: 262 MARIOLA HERBET et al.The purpos
Page 50 and 51: 264 MARIOLA HERBET et al.rosuvastat
Page 55 and 56: Influence of cloudy apple juice on
Page 65 and 66: 1-[(Imidazolin-2-yl)amino]indoline
Page 67 and 68: 1-[(Imidazolin-2-yl)amino]indoline
Page 69 and 70:
1-[(Imidazolin-2-yl)amino]indoline
Page 71 and 72:
Page 73:
Page 76 and 77:
290 TOMASZ KOSMALSKI et al.the lite
Page 78 and 79:
292 TOMASZ KOSMALSKI et al.Antibact
Page 80 and 81:
294 TOMASZ KOSMALSKI et al.66.49(19
Page 83 and 84:
Acta Poloniae Pharmaceutica ñ Drug
Page 85 and 86:
Synthesis and in vitro antiprolifer
Page 87 and 88:
Page 89 and 90:
Page 91:
Page 94 and 95:
308 ASHRAF M. MOHAMED et al.Cevipab
Page 96 and 97:
310 ASHRAF M. MOHAMED et al.solvent
Page 98 and 99:
312 ASHRAF M. MOHAMED et al.Table 2
Page 100 and 101:
314 ASHRAF M. MOHAMED et al.Table 3
Page 102 and 103:
316 ASHRAF M. MOHAMED et al.teristi
Page 104 and 105:
318 ASHRAF M. MOHAMED et al.20. Che
Page 106 and 107:
320 MANSURAH A. ABDULAZEEZ et al.an
Page 108 and 109:
322 MANSURAH A. ABDULAZEEZ et al.GC
Page 110 and 111:
324 MANSURAH A. ABDULAZEEZ et al.Ta
Page 112 and 113:
326 MANSURAH A. ABDULAZEEZ et al.in
Page 114 and 115:
328 MANSURAH A. ABDULAZEEZ et al.34
Page 116 and 117:
330 SAMINA AFZAL et al.is used as a
Page 118 and 119:
332 SAMINA AFZAL et al.Detection of
Page 120 and 121:
334 SAMINA AFZAL et al.CONCLUSIONAm
Page 122 and 123:
336 BEATA PASKER et al.inhibitory o
Page 124 and 125:
338 BEATA PASKER et al.Figure 2. Ef
Page 126 and 127:
340 BEATA PASKER et al.In conclusio
Page 128 and 129:
342 NASER VAHED DEHKORDI et al.EXPE
Page 130 and 131:
344 NASER VAHED DEHKORDI et al.Anti
Page 133 and 134:
Page 135 and 136:
Dissolution properties and kinetic
Page 137 and 138:
Page 139 and 140:
Page 141:
Page 144 and 145:
358 OLADAPO A. ADETUNJI et al.In th
Page 146 and 147:
360 OLADAPO A. ADETUNJI et al.that
Page 148 and 149:
362 OLADAPO A. ADETUNJI et al.Figur
Page 150 and 151:
364 OLADAPO A. ADETUNJI et al.Figur
Page 153 and 154:
Page 155 and 156:
In vitro antimicrobial activity of
Page 157 and 158:
Page 159 and 160:
Page 161:
Page 164 and 165:
378 SHENG LI et al.the developed an
Page 166 and 167:
380 SHENG LI et al.Fisherís exact
Page 168 and 169:
382 SHENG LI et al.Arabia and Jorda
Page 170 and 171:
384 MAGDALENA RATAJCZAK et al.g/mL.
Page 172 and 173:
386 MAGDALENA RATAJCZAK et al.ing d
Page 175 and 176:
Page 177 and 178:
Use of medicines among students of
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Cytotoxicity and antiglucosidase po
Page 187:
Cytotoxicity and antiglucosidase po
Page 190 and 191:
404 ANNA CWYNAR et al.was used to r
Page 192 and 193:
406 ANNA CWYNAR et al.Consequently,
show all

acta 2_2015

Create successful ePaper yourself

Delete template?

Save as template?